Home Clinical trials For patients Ovary REGN5668

REGN5668

Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)


Open
Trial drug
REGN5668, REGN4018, Cemiplimab
Grade
High grade, Low grade
Prior lines
1, 2, 3, 4
Histology
Serous, Endometrioid Clear-cell Mucinous Other (bv. mixed/rare)
Platin
Platinum sensitive
Platinum resistant
Primary platinum refractory
Secondary platinum refractory
Phase
1/2

Treatment

This study consists of two different treatment options: 

  • REGN5668 + Cemiplimab
  • REGN5668 + REGN4018

REGN5668, REGN4018 and Cemiplimab will be administered intravenously.

No randomisation will be performed in this trial. You will be allocated to one of both groups depending on the characteristics of your disease.

REGN5668 versie2

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.